AstraZeneca PLC — Regulatory Filings 2016

Oct 7, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of October 2016

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1. AZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US dated 07th October 2016

This announcement contains insi de information

7 October 2016 07:00

ASTRAZENECA ENTERS AGREEMENT WITH

CILAG GMBH INTERNATIONAL TO DIVEST RIGHTS TO RHINOCORT AQUA

OUTSIDE THE US

AstraZeneca today announced that it has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.

Rhinocort Aqua is a nasal spray indicated for allergic and non-allergic rhinitis ( inflammation of the inside of the nose) , and for the treatment of nasal polyps (swelling of the nasal lining) . The active ingredient is the anti-inflammatory medicine budesonide.

Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca, said: "This agreement allows us to concentrate our efforts in Respiratory as one of our three strategic therapy areas, on transforming the treatment of asthma and COPD, where budesonide remains a key component of our marketed as well as pipeline medicines."

Financial considerations

The agreement is subject to customary closing conditions and is expected to complete in the fourth quarter of 2016. As AstraZeneca will not maintain a significant ongoing interest in Rhinocort Aqua , the $330 million payment received from Cilag GmbH International upon completion of the transaction will be recognised as Other Operating Income in the Company's financial statements. The transaction does not include the transfer of any AstraZeneca employees or facilities and does not impact the Company's financial guidance for 2016.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory, Cardiovascular & M e tabolic Diseases, and Oncology. The Company is also selectively active in Neuroscience and Autoimmunity. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

| Media Enquiries — Neil
Burrows | UK/Global | +44 203
749 5637 |
| --- | --- | --- |
| Vanessa
Rhodes | UK/Global | +44 203
749 5736 |
| Karen
Birmingham | UK/Global | +44 203
749 5634 |
| Rob
Skelding | UK/Global | +44 203
749 5821 |
| Jacob
Lund | Sweden | +46
8 553 260 20 |
| Michele
Meixell | US | +1 302
885 2677 |
| Investor Relations | | |
| UK | | |
| Thomas
Kudsk Larsen | | +44 203
749 5712 |
| Craig
Marks | Finance,
Fixed Income, M&A | +44
7881 615 764 |
| Nick
Stone | Respiratory | +44 203
749 5716 |
| Henry
Wheeler | Oncology | +44 203
749 5797 |
| Christer
Gruvris | Neuroscience
& Autoimmunity | +44 203
749 5711 |
| US | | |
| Lindsey
Trickett | Cardiovascular
& Metabolic Diseases | +1 240
543 7970 |
| Mitchell
Chan | Oncology | +1 240
477 3771 |
| Toll-free | | +1 866
381 7277 |

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 07 October 2016
Name:
Adrian Kemp
Title:
Company Secretary

page break